PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
187.54%
Cash & equivalents growing 187.54% while CRVO's declined -12.22%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
187.23%
Below half of CRVO's -12.22%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
168.93%
Below half of CRVO's -13.12%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-20.60%
Below half CRVO's 12.65%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.19%
Below half of CRVO's 0.07%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
164.96%
Below half of CRVO's -7.38%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-45.35%
Above 1.5x CRVO's -27.71%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-33.08%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
43.64%
Higher Deferred Revenue (Current) Growth compared to CRVO's zero value, indicating better performance.
-68.51%
Less than half of CRVO's 7.17%. David Dodd sees fewer expansions in other current obligations.
-61.96%
Above 1.5x CRVO's -10.50%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-61.96%
Above 1.5x CRVO's -5.33%. Michael Burry sees a potential leverage warning sign.
19.13%
Higher Common Stock (Book Value) Growth compared to CRVO's zero value, indicating worse performance.
-3.37%
0.5-0.75x CRVO's -4.67%. Martin Whitman is wary of weaker retention or lower profitability.
-26.34%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
955.36%
Below half CRVO's -7.63%. Michael Burry sees potential underperformance in building shareholder capital.
164.96%
Below half CRVO's -7.38%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-33.08%
Higher Total Debt Growth compared to CRVO's zero value, indicating worse performance.
-197.28%
Less than half of CRVO's 12.22%. David Dodd sees better deleveraging or stronger cash buildup than competitor.